Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer

Volume: 11, Issue: 504
Published: Aug 7, 2019
Abstract
Longitudinal analysis of circulating tumor DNA (ctDNA) has shown promise for monitoring treatment response. However, most current methods lack adequate sensitivity for residual disease detection during or after completion of treatment in patients with nonmetastatic cancer. To address this gap and to improve sensitivity for minute quantities of residual tumor DNA in plasma, we have developed targeted digital sequencing (TARDIS) for multiplexed...
Paper Details
Title
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer
Published Date
Aug 7, 2019
Volume
11
Issue
504
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.